Replies to post #1755 on Sarepta Therapeutics (SRPT)

[h2145h]

From Reuters this morning: Nine of the 10 brokerages tracked by Thomson Reuters StarMine recommend buying Sarepta shares. Their mean price target is $42; five of the analysts rate the company a "strong buy. Sell on the news is being carried to ridiculous extremes>